ArticleRevista da Associacao Medica Brasileira (1992)2025
A retrospective study: management of Rhizobium radiobacter-associated bloodstream infections in pediatric hematology and oncology patients.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rhizobium radiobacter bloodstream infection associated with long-term central venous access in an infant with Pompe disease.Le infezioni in medicina · 2026Article
- Distribution and seasonal abundance of medically important flies in Sharkia Governorate, Egypt and their associated bacteria.PloS one · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRhizobium spp. strains (formerly classified as Agrobacterium based on 16S rDNA analysis) are aerobic, motile, oxidase-positive, non-spore-forming gram-negative bacilli. Clinical manifestations associated with Rhizobium radiobacter infections vary widely, with bacteremia typically linked to intravenous catheter use.
methodsThis study analyzes the clinical and laboratory characteristics of 11 pediatric hematology and oncology patients at a tertiary referral hospital who had Rhizobium radiobacter-associated bloodstream infections over a 3-month period.
resultsNine of the patients were male, and hematologic malignancy was the primary diagnosis in seven patients. Common risk factors included hospitalization within the last month, chemotherapy treatment, and the presence of an indwelling central venous catheter in all cases. Rhizobium radiobacter growth was detected an average of 13.5±16.6 days (range 1-54 days) after hospital admission, with 36% of patients being neutropenic at the time of culture positivity. Rhizobium radiobacter growth was detected in both catheter and peripheral blood cultures in six patients, whereas the microorganism was isolated exclusively from catheter cultures in four patients. Ten patients received antibiotic lock therapy, predominantly with amikacin (90%). Systemic antibiotic treatment involved a combination of beta-lactam and aminoglycoside antibiotics in 10 patients. Culture sterility was achieved in nine patients by the third day of antibiotic treatment. There were no cases of catheter extraction, thrombophlebitis, cardiac vegetation, reproductive complications, or mortality.
conclusionIn this first pediatric case series utilizing antibiotic lock therapy, effective treatment, strict isolation, and surveillance screenings led to favorable clinical outcomes for Rhizobium radiobacter-associated bloodstream infections in children with hematologic and oncologic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.